Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2...

Date First Received: November 3, 2006

Last Updated: November 3, 2006

Verified by: AstraZeneca, February 2003

Clinical Trial Phase: Phase 4 | Start Date: February 2003

Overall Status: Completed

Estimated Enrollment: 3889

Brief Summary

Official Title: “Evaluation of the Efficacy of Rosuvastatin in Daily Practice (TARGET)”

In this study the effect of the switch to rosuvastatin from another statin (fluvastatin, pravastatin, simvastatin, atorvastatin) was evaluated in high-risk patients with and without evident CHD and LDL-C ≥ 3.2 mmol/l. This was done in a large observational study (TARGET) representing daily practice. Primary end points analysis was the percentage of patients reaching the target of LDL-C < 3.2 mmol/l. Secondary outcomes were the changes of LDL-C, HDL-C, TC, Triglycerides (TG) and TC/HDL-C-ratio from baseline.

Study Type: Observational

Study Design: Natural History, Longitudinal, Defined Population, Prospective Study

Criteria for Participation in this Clinical Trial

Inclusion Criteria:

  • High-risk patients with and without evident CHD who had LDL-C > 3.2 mmol/l and were treated at that moment with HMG-CoA-reductase inhibitor apart from rosuvastatin.
  • Patients were aged >18 years and <70 years (men) and < 75 years (women).

Exclusion Criteria:

  • Treatment with atorvastatin 40 or 80 mg or simvastatin 80 mg
  • Patients familiar with muscular pain, myopathy or liver function disorders (inclusive elevation of serum transaminases) and/or contra-indications for treatment with rosuvastatin

Gender Eligibility for this Clinical Trial: Both

Minimum Age for this Clinical Trial: 18 Years

Maximum Age for this Clinical Trial: 75 Years

Are Healthy Volunteers Accepted for this Clinical Trial?: No

Clinical Trial Sponsor Information

Lead Sponsor: AstraZeneca

Overall Clinical Trial Officials and Contacts

Ingrid van Geel, MD Study Chair AstraZeneca  

Additional Information

Information obtained from ClinicalTrials.gov on August 20, 2008

Link to the current ClinicalTrials.gov record. http://clinicaltrials.gov/show/NCT00396110

Study ID Number: 25V06

ClinicalTrials.gov Identifier: NCT00396110

Health Authority: Netherlands: The Central Committee on Research Involving Human Subjects (CCMO)

Clinical Trials Authorship and Review

Clinical Trials content is provided directly by the U.S. National Institutes of Health via ClinicalTrials.gov and is not reviewed separately by ClinicalTrialsFeeds.org. Every page of specific clinical trials information contains a unique identifier which can be used to find further details directly from the National Institutes of Health.